Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer

(2013) Hideko Yamauchi et al.   Clinical Breast Cancer

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer

(2013) J.A. Davidson et al.   EUROPEAN JOURNAL OF CANCER

Laboratory-Developed Test—SynFRAME: An Approach for Assessing Laboratory-Developed Tests Synthesized from Prior Appraisal Frameworks

(2012) John Hornberger et al.   Genetic Testing and Molecular Biomarkers

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

(2011) Gong Tang et al.   BREAST CANCER RESEARCH AND TREATMENT

St. Gallen 2011: Summary of the Consensus Discussion

(2011) Michael Gnant et al.   Breast Care

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

(2010) Masahide Kondo et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population

(2010) Masakazu Toi et al.   CANCER

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan

(2010) Hiroshi Ishiguro et al.   CLINICAL THERAPEUTICS

The Breast Cancer Working Group Presentation was Divided into Three Sections: The Epidemiology, Pathology and Treatment of Breast Cancer

(2010) M. Toi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

(2010) D. T. Tsoi et al.   ONCOLOGIST

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

(2009) Kyoko Yorozuya et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Lifetime and Age-Conditional Probabilities of Developing or Dying of Cancer in Japan

(2008) K.-i. Kamo et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of life valuations of mammography screening

(2008) Amy E. Bonomi et al.   QUALITY OF LIFE RESEARCH